Physician profile
Christopher Ramos
NPI 1932425907
$4,406.03
in general payments reported to CMS, 2019-2025
29 companies · $794 in 2025
The $794 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $896 · 2020: $125 · 2021: $436 · 2022: $877 · 2023: $854 · 2024: $423 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,071.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,579.80 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $486.76 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $387.84 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Celgene Corporation | $366.22 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $265.19 | 2019-2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $236.89 | 2023-2025 | Dupixent |
| Qol Medical, LLC | $162.56 | 2019-2022 | |
| Braintree Laboratories, INC. | $91.70 | 2019-2023 | Suflave |
| Ironwood Pharmaceuticals, INC | $89.69 | 2019-2023 | Linzess |
| Redhill Biopharma INC. | $89.42 | 2021-2023 | Talicia |
| Daiichi Sankyo INC. | $73.44 | 2019-2023 | Injectafer |
| Pfizer INC. | $59.63 | 2021-2022 | |
| Genzyme Corporation | $58.89 | 2022-2025 | |
| Allergan, INC. | $56.51 | 2019-2020 | |
| Lilly USA, LLC | $54.27 | 2025 | Omvoh |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $49.01 | 2019-2023 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $48.21 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $42.32 | 2023 | Zeposia |
| Ethicon US, LLC | $34.53 | 2019 | |
| Merck Sharp & Dohme LLC | $32.33 | 2021-2022 | |
| Celltrion USA INC. | $27.74 | 2025 | Vegzelma |
| Gilead Sciences, INC. | $20.16 | 2019 | |
| Fresenius Kabi USA, LLC | $17.47 | 2024 | Idacio |
| Enterra Medical, INC. | $17.30 | 2024 | |
| Aimmune Therapeutics, INC. | $15.34 | 2025 | Zenpep |
| Alfasigma USA, INC. | $14.49 | 2020 | |
| Micro-Tech Endoscopy USA, INC. | $14.45 | 2019 | |
| Ferring Pharmaceuticals INC. | $13.87 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$65,805.23 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.